Study finds why asthma drugs help some children but not others

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The American Journal of Managed Care

FDA Approves Depemokimab for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...
Clinical Advisor

FDA Greenlights Exdensur for Severe Eosinophilic Asthma

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Medical Dialogues

FDA Approves Depemokimab-ulaa as First Twice-Yearly Biologic for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...